One sample per household
A patient might use the upper leg, upper arm, or stomach as the injection site and change them from time to time
Source: #Healthcare #Pharma #GLP1 #Obesity #HealthPolicy #Innovation GLP-1 drugs for obesity: Cost-effective, but coverage uncertain As reported by Axios International Vitals, the leading GLP-1 drugs from Novo Nordisk and Eli Lilly and Company are now becoming cost-effective for treating obesity, according to a new analysis from the Institute for Clinical and Economic Review (ICER): Why does this matter
Its highly doubtful that all of the drugs people take will be for sale through this channel, Cubanski said
Enjoy additional articles per month
Age-related changes in renal function, hepatic metabolism, and tissue perfusion theoretically could influence peptide clearance and distribution, though no studies have systematically examined age effects